Dipeptidyl Peptidase 4 Inhibitors and Risk of Inflammatory Bowel Disease: Real-world Evidence in U.S. Adults.
Tiansheng WangJeff Y YangJohn B BuseVirginia PateHuilin TangEdward L BarnesRobert S SandlerTil StürmerPublished in: Diabetes care (2019)
Our population-based cohort study of U.S. adults with diabetes suggests that short-term DPP4i treatment does not increase IBD risk.